Wall Street Zen Upgrades Immix Biopharma (NASDAQ:IMMX) to “Hold”

by · The Cerbat Gem

Immix Biopharma (NASDAQ:IMMX – Get Free Report) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

Other equities research analysts have also issued research reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immix Biopharma in a research note on Wednesday, October 8th. HC Wainwright lifted their price objective on Immix Biopharma from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Friday, September 12th. Finally, Zacks Research downgraded Immix Biopharma from a “strong-buy” rating to a “hold” rating in a report on Monday, August 25th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $8.00.

View Our Latest Research Report on Immix Biopharma

Immix Biopharma Stock Performance

IMMX opened at $7.07 on Friday. The stock has a market capitalization of $237.41 million, a PE ratio of -9.18 and a beta of 0.33. The stock’s 50 day moving average price is $3.87 and its 200-day moving average price is $2.89. Immix Biopharma has a 52-week low of $1.34 and a 52-week high of $7.73.

Immix Biopharma (NASDAQ:IMMX – Get Free Report) last released its quarterly earnings results on Friday, November 7th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.05). Research analysts forecast that Immix Biopharma will post -0.87 EPS for the current fiscal year.

Hedge Funds Weigh In On Immix Biopharma

Large investors have recently made changes to their positions in the business. Citadel Advisors LLC purchased a new stake in shares of Immix Biopharma in the 3rd quarter worth approximately $188,000. United Capital Financial Advisors LLC purchased a new position in Immix Biopharma during the third quarter valued at $148,000. Imprint Wealth LLC bought a new stake in Immix Biopharma in the third quarter worth $141,000. Susquehanna International Group LLP grew its stake in shares of Immix Biopharma by 78.8% in the third quarter. Susquehanna International Group LLP now owns 90,858 shares of the company’s stock worth $190,000 after acquiring an additional 40,032 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Immix Biopharma by 4.5% during the third quarter. Vanguard Group Inc. now owns 730,162 shares of the company’s stock valued at $1,526,000 after acquiring an additional 31,625 shares in the last quarter. 11.26% of the stock is currently owned by hedge funds and other institutional investors.

Immix Biopharma Company Profile

(Get Free Report)

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.

See Also